Literature DB >> 24166895

Can liver transplantation provide the statistical cure?

Alessandro Cucchetti1, Alessandro Vitale, Matteo Cescon, Martina Gambato, Lorenzo Maroni, Matteo Ravaioli, Giorgio Ercolani, Patrizia Burra, Umberto Cillo, Antonio D Pinna.   

Abstract

Liver transplantation (LT) represents the only chance of long-term survival for patients with end-stage liver disease. When the mortality rate for transplant patients returns to the same level as that for the general population, they can be considered statistically cured. However, cure models in the setting of LT have never been applied. Data from 1371 adult patients undergoing LT for the first time between January 1999 and December 2012 at 2 Italian centers were reviewed in order to establish probabilities of being cured by LT. A parametric Weibull model was applied to compare the mortality rate after LT to the rate expected for the general population (matched by sex and age). The observed 3-, 5-, and 10-year overall survival rates after LT were 77.8%, 73.3%, and 65.6%, respectively, and they did not differ between the 2 centers (P = 0.37). The cure fraction for the entire study population was 63.4% (95% confidence interval = 52.6%-72.0%), and the time to cure was 10 years with a 90% confidence level. The best cure fraction was observed for younger recipients without hepatitis C virus (HCV) who had favorable donor-recipient matches, that is, low Donor Model for End-Stage Liver Disease (D-MELD) scores (90.1%); conversely, the lowest probability was observed for elderly HCV recipients with high D-MELD scores (34.6%). The time to cure was 6.22 years for non-HCV patients and 14.78 years for HCV patients. The median survival time for uncured patients was 2.29 years. Among uncured recipients, the longest survival time was observed for younger patients (7.31 years). In conclusion, we provide here a new clinical measure for LT suggesting that survival after transplantation can approximate that of the general population and provide a statistical cure.
© 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 24166895     DOI: 10.1002/lt.23783

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis.

Authors:  Alessandro Cucchetti; Matteo Serenari
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

Review 2.  Surgery and Hepatocellular Carcinoma.

Authors:  Nobuhisa Akamatsu; Umberto Cillo; Alessandro Cucchetti; Matteo Donadon; Antonio Daniele Pinna; Guido Torzilli; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

3.  Comment on: 'Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'.

Authors:  Alessandro Cucchetti; Matteo Cescon; Antonio Daniele Pinna
Journal:  Br J Cancer       Date:  2016-06-23       Impact factor: 7.640

Review 4.  Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.

Authors:  Saleh Daher; Muhammad Massarwa; Ariel A Benson; Tawfik Khoury
Journal:  J Clin Transl Hepatol       Date:  2017-12-17

5.  Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival.

Authors:  Aya Nomura; Masatoshi Ishigami; Takashi Honda; Teiji Kuzuya; Yoji Ishizu; Takanori Ito; Hideya Kamei; Yasuharu Onishi; Yasuhiro Ogura; Mitsuhiro Fujishiro
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.